Hyperbilirubinemia May Protect Neonates from SARS-CoV-2 Infection: A Yellow Eye View of COVID-19
DOI:
https://doi.org/10.21467/preprints.72Abstract
A consensus was developing based on immunity, children and aged are more susceptible to SARS-CoV-2 infection than healthy young adults. Along this line of concept neonates are most vulnerable to COVID-19; however, and in fact, it is not the case. Neonates born to COVID-19 mothers are less or not affected. Among the new-born 60-80% develop hyperbilirubinemia, known as neonatal jaundice. Bilirubin in plasma up to certain level is beneficial for many reasons, including free radical scavenging. In view of this, I hypothesize that hyperbilirubinemia may protect new-born from COVID-19, and sufficient care necessary for antiviral-induced liver damage during the treatment of SARS-CoV-2 infection.
Keywords:
Bilirubin, Antioxidant, Neonatal Jaundice, SARS-CoV-2, COVID-19, Vertical transmission, Liver finction, TMPRSS2, Serine protease, Furin, ACE2Downloads
References
Fujiwara R, Haag M, Schaeffeler E, et al. (2018) Systemic regulation of bilirubin homeostasis: Potential benefits of hyperbilirubinemia. Hepatology, 67(4):1609-1619. doi: 10.1002/hep.29599.
Patra SK, Mandal AK and Pal MK (1999) State of aggregation of bilirubin in aqueous solution: principal component analysis approach. J PhotochemPhotobiol A: Chem, 122: 23-31.
Patra SK and Pal MK (1997) Spectroscopic probes of the individual and combined effects of Triton X-100 and chloroform on serum albumins and serum-albumin:bilirubin complexes. Eur J Biochem, 246: 658-664.
Gondalez-Oddone MV (1946) Bilirubin, bromsulfalein, bile acids, alkaline phosphatase and cholesterol of thoracic duct lymph in experimental regurgitation jaundice. ProcSocExpBiol Med. 1946 Oct;63(1):144-7.
Wabnitz CH (1951) Hyperbilirubinemia I. A rapid screening test for its detection. J Lab Clin Med. 37(3):477-480.
Maisels MJ and Gifford K (1986) Normal serum bilirubin levels in the newborn and the effect of breast-feeding. Pediatrics, 78: 837-843.
Schachter D (1957) Nature of the glucuronide in direct-reacting bilirubin. Science, 126: 507-508.
Gardikas C, Kench JE, Wilkinson JF (1947) Serum bilirubin and the van den Bergh reaction. Nature, 159: 842.
Van Wagner LB and Green RM (2015)Evaluating elevated bilirubin levels in asymptomatic adults. JAMA, 313: 516-517. doi: 10.1001/jama.2014.12835.
Grein J, Ohmagari N, Shin D, et al. (2020) Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med, 2020 Apr 10. doi: 10.1056/NEJMoa2007016.
Hung I F-N, Lung K-C, Tso E Y-K et al. (2020) Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. The Lancet, https://doi.org/10.1016/S0140-6736(20)31101-6
Duan K, Liu B, Li C, Zhang H, et al. (2020) Effectiveness of convalescent plasma therapy in severe COVID-19 patients. ProcNatlAcadSci U S A. 2020 Apr 28;117(17):9490-9496. doi: 10.1073/pnas.2004168117.
Zhang ZJ, Yu XJ, et al. (2020) Novel coronavirus infection in newborn babies under 28 days in China. Eur Respir J. 2020 Apr 8. pii: 2000697. doi: 10.1183/13993003.00697-2020.
Basha S, Surendran N and Pichichero M (2014) Immune responses in neonates. Expert Rev ClinImmunol. 10(9):1171-84. doi: 10.1586/1744666X.2014.942288.
Jennewein MF, Butler AL and Alter G. (2018) Neonate-omics: charting the unknown immune response in early life. Cell, 174:1051-1053.
Kollmann TR, Kampmann B, Mazmanian SK, Marchant A and Levy O (2017) Protecting the newborn and young infant from infectious diseases: lessons from immune ontogeny. Immunity. 2017 Mar 21;46(3):350-363. doi: 10.1016/j.immuni.2017.03.009.
Zeng L, Xia S, Yuan W, et al. (2020) Neonatal early-onset infection with SARS-CoV-2 in 33 neonates born to mothers with COVID-19 in Wuhan, China. JAMA Pediatr. 2020 Mar 26. doi: 10.1001/jamapediatrics.2020.0878
Shekerdemian LS et al. from International COVID-19 PICU Collaborative (2020) Characteristics and outcomes of Children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian pediatric intensive care units. JAMA Pediatr. 2020 May 11. doi: 10.1001/jamapediatrics.2020.1948.
(i) https://www.bbc.com/news/health-52648557 and(ii) https://www.unicef.org/eca/protecting-children-and-adolescents-disabilities-pandemic
Patra SK (2020) Outfitting COVID-19: An effective therapeutic approach. AIJR Preprints, 41: Version-1. https://preprints.aijr.org/index.php/ap/preprint/view/41
Kirchdoerfer RN, Ward AB (2019) Structure of the SARS?CoV nsp12 polymerase bound to nsp7 and nsp8 co?factors. Nat Commun, 10: 2342-2350.
teVelthuis AJW, Arnold JJ, Cameron CE, van den Worm SHE and Snijder EJ (2010) The RNA polymerase activity of SARS?coronavirus nsp12 is primer dependent. Nucleic Acids Res, 38: 203? 214.
Kim D, Lee JY, Yang JS, et al. (2020) The architecture of SARS-CoV-2 transcriptome. Cell, pii: S0092-8674(20)30406-2. doi: 10.1016/j.cell.2020.04.011
Lu R, Zhao X, Li J, Niu P, Yang B, et al. (2020)Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet,395(10224):565-574. doi: 10.1016/S0140-6736(20)30251-8.
Forster P, Forster L, Renfrew C and Forster M (2020) Phylogenetic network analysis of SARS-CoV-2 genomes. ProcNatlAcadSci USA, pii: 202004999. doi: 10.1073/pnas.2004999117.
Andersen KG, Rambaut A, Lipkin WI, Holmes EC and Garry RF (2020) The proximal origin of SARS-CoV-2. Nat Med, 26: 450-452. doi: 10.1038/s41591-020-0820-9.
Dasgupta R (2020) A genetic perspective of 2019-nCoV in relation to cross species transmission. AIJR Preprints, 39: version 1. https://preprints.aijr.org/index.php/ap/preprint/view/39
Pachetti M, Marini B, et al. (2020) Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant. J Transl Med. 18: 179. doi: 10.1186/s12967-020-02344-6.
Wang C, Liu Z, Chen Z, Huang X, Xu M, He T and Zhang Z (2020) The establishment of reference sequence for SARS-CoV-2 and variation analysis. J Med Virol, 2020 Mar 13, doi: 10.1002/jmv.25762.
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N et al. (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell, 181: 271-280.e8
Shulla A, Heald-Sargent T, Subramanya G, Zhao J, Perlman S and Gallagher T (2011) A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry. J. Virol., 85 (2011), pp. 873-882
Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT and Veesler D (2020) Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell, 181: 281-292.e6
Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS and McLellan JS (2020) Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science, 367: 1260-1263
Hoffmann M, Kleine-Weber H and Pöhlmann S (2020) A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol Cell. pii: S1097-2765(20)30264-1. doi: 10.1016/j.molcel.2020.04.022.
Dahms SO, Hardes K, Becker GL, Steinmetzer T, Brandstetter H and Then ME (2014) X-ray structures of human furin in complex with competitive inhibitors. ACS ChemBiol, 9: 1113–1118.
Muus C, Luecken MD, Eraslan G, et al. (2020) Integrated analyses of single-cell atlases reveal age, gender, and smoking status associations with cell type-specific expression of mediators of SARS-CoV-2 viral entry and highlights inflammatory programs in putative target cells. bioRxiv preprint doi: https://doi.org/10.1101/2020.04.19.049254.
Patra SK and Pal MK (1998) On the effect of visible light irradiation on bilirubin and bilirubin bound to serum albumins: an insight into the phototherapy of neonatal jaundice. J Indian ChemSoc, 75: 148-150.
Hansen R, Gibson S, De PaivaAlves E, et al. (2018) Adaptive response of neonatal sepsis-derived Group B Streptococcus to bilirubin. Sci Rep. 2018 Apr 24;8(1):6470. doi: 10.1038/s41598-018-24811-3.
McDonagh AF and Palma LA (1980) Hepatic excretion of circulating bilirubin photoproducts in the Gunn rat. J Clin Invest, 66: 1182-1185.
Chowdhury JR, Chowdhury NR, Bhargava MM, Arias IM (1979) Purification and partial characterization of rat liver bilirubin glucuronoside glucuronosyltransferase. J BiolChem, 254(17):8336-8339.
Bosma PJ, Seppen J, Goldhoorn B, Bakker C, Oude Elferink RP, Chowdhury JR, Chowdhury NR and Jansen PL (1994) Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man. J BiolChem, 269: 17960-17964.
Iyanagi T, Emi Y and Ikushiro S (1998) Biochemical and molecular aspects of genetic disorders of bilirubin metabolism. BiochimBiophysActa, 1407: 173-184.
Patra SK and Pal MK (1997) Red edge excitation shift emission spectroscopic investigation of serum albumins and serum albumin-bilirubin complexes. Spectrochim Acta A MolBiomolSpectrosc. 53A(10):1609-1614.
Tan KL (1996) Phototherapy for neonatal jaundice. Acta Paediatr, 85: 277-279.
Dong L, Tian J, He S, et al. (2020) Possible vertical transmission of SARS-CoV-2 from an infected mother to her newborn. JAMA. 2020 Mar 26. doi: 10.1001/jama.2020.4621.
Chen H, Guo J,Wang C, et al. (2020) Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet. 2020;395(10226):809-815. doi:10.1016/S0140-6736(20)30360-3
Paliogiannis P and Zinellu A (2020) Bilirubin levels in patients with mild and severe Covid-19: a pooled analysis. Liver Int. 2020 Apr 18. doi: 10.1111/liv.14477.
Lei F, Liu YM, Zhou F, Qin JJ, et al. (2020) Longitudinal association between markers of liver injury and mortality in COVID-19 in China. Hepatology. 2020 May 2. doi: 10.1002/hep.31301
Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, Li Z, Zhou G, Gou J, Qu J, Sun Y, Liu Y, He Q, Chen J, Liu L, Xu L (2020) COVID-19: Abnormal liver function tests. J Hepatol,pii: S0168-8278(20)30218-X. doi: 10.1016/j.jhep.2020.04.006.
Huang C, Wang Y, Li X, Ren L, et al. (2020)Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 395:497-506. doi: 10.1016/S0140-6736(20)30183-5.
Patra SK (2020) Perspective on Accelerating the Mutation Rate of SARS-CoV-2for a Better Way of COVID-19 Treatment;Enhanced Mutation Therapy of COVID-19. AIJR Preprints,62, version 1. https://preprints.aijr.org/index.php/ap/preprint/view/62
Downloads
Posted
Section
Categories
License
Copyright (c) 2020 Samir PATRA
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Any non-commercial use, distribution, adaptation, and reproduction in any medium is permitted as long as the original work is properly cited. However, caution and responsibility are required when reusing as the articles on the preprint server are not peer-reviewed. Readers are advised to check for the availability of any updated or peer-reviewed version.
